Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the market valuation of the company partnered with UCRiverside for MED6-189 development by June 30, 2025?
Under $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
Over $10 billion • 25%
Stock market reports and financial news
Kalihinol Analog MED6-189 Shows Promise Against Drug-Resistant Malaria Parasite
Sep 27, 2024, 07:28 AM
A synthetic compound, MED6-189, a kalihinol analog, has shown promise against both drug-sensitive and drug-resistant strains of the malaria parasite Plasmodium falciparum. The compound disrupts apicoplast function and vesicular trafficking in the parasite, effectively killing it. This discovery, highlighted in a study published in Science, demonstrated efficacy in a humanized mouse model of malaria. Research by @UCRiverside and @ScienceMagazine indicates that MED6-189 could be a significant advancement in the fight against malaria.
View original story
Less than $200M • 25%
$200M - $400M • 25%
$400M - $600M • 25%
More than $600M • 25%
Under $500M • 25%
$500M - $1B • 25%
$1B - $1.5B • 25%
Over $1.5B • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Increases by more than 50% • 25%
Increases by 25% to 50% • 25%
Changes by less than 25% • 25%
Decreases • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $5 billion • 25%
More than $5 billion • 25%
Below $3 billion • 25%
$3 billion to $5 billion • 25%
$5 billion to $7 billion • 25%
Above $7 billion • 25%
Less than $100B • 25%
$100B to $150B • 25%
$150B to $200B • 25%
More than $200B • 25%
Above $1 billion • 25%
Between $750 million and $1 billion • 25%
Between $500 million and $750 million • 25%
Below $500 million • 25%
Under $100M • 25%
$100M to $300M • 25%
$300M to $500M • 25%
Over $500M • 25%
No • 50%
Yes • 50%
1-2 countries • 25%
7 or more countries • 25%
5-6 countries • 25%
3-4 countries • 25%